Argus lowered shares of AstraZeneca (NASDAQ:AZN) from a buy rating to a hold rating in a research report sent to investors on Monday morning, PriceTargets.com reports.
A number of other research firms also recently issued reports on AZN. Piper Sandler cut their price target on AstraZeneca from $179.00 to $175.00 and set an overweight rating for the company in a research note on Sunday, December 13th. Barclays restated an overweight rating on shares of AstraZeneca in a research report on Monday, March 8th. Jefferies Financial Group upgraded shares of AstraZeneca from a hold rating to a buy rating in a research report on Monday, March 22nd. Societe Generale restated a buy rating on shares of AstraZeneca in a research note on Tuesday, March 23rd. Finally, SVB Leerink decreased their target price on AstraZeneca from $64.00 to $63.00 and set an outperform rating on the stock in a report on Monday, March 8th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $83.40.
Shares of AZN stock opened at $49.84 on Monday. The firm has a market capitalization of $130.81 billion, a PE ratio of 51.92, a P/E/G ratio of 1.18 and a beta of 0.55. The company has a 50 day moving average price of $49.19 and a 200-day moving average price of $51.13. AstraZeneca has a 52 week low of $46.48 and a 52 week high of $64.94. The company has a quick ratio of 0.76, a current ratio of 0.96 and a debt-to-equity ratio of 1.34.
The firm also recently declared a semi-annual dividend, which was paid on Monday, March 29th. Shareholders of record on Friday, February 26th were paid a $0.95 dividend. This represents a yield of 2.7%. The ex-dividend date was Thursday, February 25th. This is a positive change from AstraZeneca’s previous semi-annual dividend of $0.45. AstraZeneca’s dividend payout ratio is presently 106.29%.
Several institutional investors have recently made changes to their positions in the company. Arkadios Wealth Advisors purchased a new stake in AstraZeneca during the 4th quarter valued at approximately $28,000. HM Payson & Co. purchased a new position in shares of AstraZeneca in the 3rd quarter worth $30,000. Hoover Financial Advisors Inc. purchased a new stake in shares of AstraZeneca during the 4th quarter valued at about $30,000. Tsfg LLC raised its position in shares of AstraZeneca by 67.4% during the 4th quarter. Tsfg LLC now owns 636 shares of the company’s stock valued at $32,000 after buying an additional 256 shares in the last quarter. Finally, Concord Wealth Partners purchased a new position in AstraZeneca in the fourth quarter worth about $34,000. Institutional investors and hedge funds own 15.57% of the company’s stock.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases.
Further Reading: Options Trading
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.